ClinicalTrials.gg
CompletedNCT03381235Updated Dec 26, 2018

Exercise and RP (AVAMC and Emory)

An interventional study of Spin exercise in Retinitis Pigmentosa, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to look in humans at the relationship between moderate or little exercise and their potential effects on the retina in patients with Retinitis Pigmentosa (RP).

Read the detailed description

Human studies have shown that regular exercise may have positive effects on common degenerative diseases such as Alzheimer's disease. Exercise has also shown to improve conditions the eye such as macular degenerations, glaucoma, and cataracts. Mice with retinal degeneration which were exposed to exercise showed that it helped to slow the rate of degeneration. The purpose of this study is to look in humans at the relationship between moderate or little exercise and their potential effects on the retina in patients with Retinitis Pigmentosa (RP).

02

Conditions studied

  • Retinitis Pigmentosa

Keywords

  • Exercise
  • Quality of life
  • Progression of disease
  • Retinitis
03

In context

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

This study's enrollment of 4 is below the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Emory University is the lead sponsor of 1,405 studies on the registry; 225 are open to participants now.

Of its 237 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual field no less than 10 degrees;
  • VA no worse than 20/200 in the better seeing eye.

Exclusion criteria

Exclusion Criteria:

  • Not able to tolerate exercise due to an underlying medical condition.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Moderate exercise

    Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.

    Other: Spin exercise

  • No intervention
    Mild exercise

    Sessions will be focused on balance and stretching.

Interventions

  • OtherSpin exercise

    Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.

06

What researchers measure

Primary outcomes

  1. Change in Brain-Derived Neurotrophic Factor (BDNF) level before and after exercise

    Sertum levels of BDNF in patients before and exercise program will be measured by testing blood

    Time frame: Baseline, 3 and 6 months follow up.

Secondary outcomes

  1. Change in retina vasculature before and after exercise

    Optical Coherence Tomography Angiography (OCTA) will serve as a tool to study retina vasculature, including choroidal, superficial and deep retinal vascular filling status and permeability, before and after exercise.

    Time frame: Baseline, 3 and 6 months follow up.

  2. Change in retinal thickness before and after exercise

    Change in retinal thickness will be evaluated using spectral-domain optical coherence tomography (SD-OCT) before and after exercise.

    Time frame: Baseline, 3 and 6 months follow up.

  3. Change in retinal pigment epithelium (RPE) pigmentation before and after exercise

    Change in retinal RPE pigmentation will be evaluated using Optos wide-field fundus photography before and after exercise.

    Time frame: Baseline, 3 and 6 months follow up.

  4. Change in degrees of vascular attenuation before and after exercise

    Change in degrees of vascular attenuation will be evaluated using Optos wide-field fundus photography before and after exercise.

    Time frame: Baseline, 3 and 6 months follow up.

  5. Change in amount of autofluorescence before and after exercise

    Change in amount of autofluorescence will be evaluated using autofluorescent imaging before and after exercise.

    Time frame: Baseline, 3 and 6 months follow up.

  6. Change in Goldmann Visual Field (GVF) scores

    The final result of a GVF is a diagram "island of vision." The visual field is an island with a central peak and the altitude correlates with the visual sensitivity in a given location.

    Time frame: Baseline, 3 and 6 months follow up.

  7. Change in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) score

    NEI VFQ-25 measures the range of vision-related functioning experienced by persons. The 12 subscales in the NEI VFQ-25 are general vision, near vision, distance vision, driving, peripheral vision, color vision, ocular pain, general health, and vision-specific role difficulties, dependency, social function, and mental health. The subscale scores are calculated by summing the relevant items and transforming the raw scores into a 0 to 100 scale where higher scores indicate better functioning or well-being.

    Time frame: Baseline, 3 and 6 months follow up.

07

Study locations

1 site
  • Emory Clinic, Atlanta VA Medical Center
    Atlanta, Georgia 30322, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03381235
Lead sponsor
Emory University
Responsible party
Jiong Yan (Associate Professor, Emory University) — Principal investigator
First posted
Dec 21, 2017
Start date
Feb 23, 2018
Primary completion
Nov 28, 2018
Completion
Nov 28, 2018
Last update
Dec 26, 2018

Study contacts

Jiong Yan, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion